Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836466 | 0.78 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1EDNRBEDNRA | |
| SCHEMBL1095905 | 0.78 | HSD17B10 (0.40) | MEN1KMT2AHSD17B10ALDH1A1KDM4E | |
| SCHEMBL4839724 | 0.75 | GSK3B (0.39) | HSD17B10ALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL5822652 | 0.74 | MDM2 (0.39) | MEN1KMT2AHSD17B10ALDH1A1EDNRB | |
| SCHEMBL8234450 | 0.72 | HTR2A (0.37) | HSD17B10ALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL2597846 | 0.67 | HSD17B10 (0.51) | KMT2AHSD17B10ALDH1A1KDM4EHPGD | |
| SCHEMBL27512712 | 0.67 | MEN1 (0.40) | MEN1KMT2AHSD17B10ALDH1A1KDM4E | |
| SCHEMBL1096745 | 0.66 | KDM4E (0.47) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL27512711 | 0.66 | TSHR (0.40) | MEN1KMT2AHSD17B10ALDH1A1KDM4E | |
| SCHEMBL8136999 | 0.66 | ALDH1A1 (0.47) | MEN1KMT2AHSD17B10ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2001866-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | MEN1 4514/4885KMT2A 4290/4885HSD17B10 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.